With its acquisition of Lung Therapeutics, Aileron is shifting its disease focus to orphan pulmonary and fibrosis indications. Aileron intends to advance Lung’s pipeline of first-in-class medicines to address significant unmet medical needs in orphan pulmonary and fibrosis indications, including LTI-03 for idiopathic pulmonary fibrosis (IPF) and LTI-01, for loculated pleural effusion (LPE).